Aclaris Therapeutics(US:ACRS) ZACKS·2025-10-21 17:01Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Aclaris Therapeutics (ACRS) currently holds a Momentum Style Score of B, indicating a favorable momentum characteristic [2] - The Zacks Rank for ACRS is 2 (Buy), suggesting strong potential for outperformance in the market [3] Price Performance - ACRS shares have increased by 1.6% over the past week, while the Zacks Medical - Drugs industry remained flat during the same period [5] - Over the past month, ACRS has shown a price change of 4.15%, significantly outperforming the industry's 0.45% [5] - In the last quarter, ACRS shares rose by 19.64%, and over the past year, they gained 66.12%, compared to the S&P 500's increases of 7.28% and 16.15%, respectively [6] Trading Volume - ACRS has an average 20-day trading volume of 1,004,293 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for ACRS has increased, while none have decreased, leading to a consensus estimate improvement from -$0.52 to -$0.51 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [9] Conclusion - Aclaris Therapeutics is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for investors seeking short-term gains [11]